1. Home
  2. Science
  3. Antibody formats

Our approach is based on the development of therapeutic antibodies designed to stimulate the antitumor activity of immune system cells - not only to induce tumor elimination by innate immune system cells, but also to trigger a multicellular immune response leading to sustained tumor control.

Monoclonal antibodies

Check-point inhibitors

Cancer cells have the ability to produce molecules that inhibit how NK cells function, leading to tumor escape. Monoclonal antibodies blocking inhibitory checkpoint receptors to prevent NK cell inactivation by tumor cells 

Cytotoxic antibodies

Monoclonal antibodies directed against tumor antigens activate cells of the innate immune system, such as NK cells, and trigger an antibody-dependent cell-mediated cytotoxicity (ADCC), via NK cell activating receptors, such as CD16. 

Anticorps monoclonal

NK Cell Engagers

NK cell engagers are molecules composed of antibody fragments specific to NK cells, designed to engage them against tumors. 
Our multispecific antibodies, also called NK cell engagers, bind to NKp46, with or without CD16, and the tumor antigen on the cancer cells. The co-engagement induces full NK cell activation and tumor cell lysis.
ANKET® (Antibody-based NK cell Engager Therapeutics) is Innate’s proprietary platform for developing next-generation, multi-specific NK cell engagers to treat certain types of cancer.   

ANKET

Antibody-drug conjugates (ADC) 

ADCs are able to bring cytotoxic molecules (toxins) within the cancer cells by using antibodies as a carrier.

ADC